Organizations:
Canadian Center for Vaccinology, Canadian Immunization Research Network, Dalhousie University, Entos Pharmaceuticals, GlaxoSmithKline, Government of Canada, IWK Health Centre, Medicago, National Research Council of Canada, Nova Scotia Health Authority, Public Health Agency of Canada, Sanofi, University of Saskatchewan, VIDO-InterVac, and World Health Organization
People:
Topics:
Canada's vaccine manufacturing capability, Canadian biomanufacturing, COVID-19 pandemic, COVID-19 vaccine candidates, COVID-19 vaccine development, DNA vaccines, future pandemics, global vaccine manufacturing, Government Funding, government response to COVID-19 crisis, multinational pharmaceutical companies, pandemic emergency response infrastructure, plant-based vaccines, Strategic Innovation Fund, vaccine clinical trials, vaccine manufacturing facilities, and vaccine research
Feds invest $887 million to ensure reliable vaccine supply for COVID-19, other pandemics
Mark LoweyApril 29, 2020
The federal government's investment of $887 million make Canada self-sufficient in manufacturing vaccines against COVID-19 and future pandemics, say medical and other experts. Along with Canadian-led vaccine development, Ottawa is investing in a network of small-scale vaccine manufacturing facilities that together will be able to produce enough vaccine for Canada's population during pandemics.
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 0 free articles remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.